Frontiers in Cardiovascular Medicine最新文献

{"title":"The hidden link between HIV and cardiomyopathy: unraveling HIV's impact on the heart.","authors":"Toluwalase Awoyemi, Oluwaremilekun Zeth Tolu-Akinnawo, Andrew Greek, Oluwakemi Adenuga, Chukwuebuka Asogwa, Isaac Ekundayo, Olamide Odusola, Oyinlola Fasehun, Mercy Ajayi, Onyinye Ugoala, Luther-King Fasehun, Oluwaseun Dorcas Adeleke, Michael Angarone","doi":"10.3389/fcvm.2025.1601430","DOIUrl":"10.3389/fcvm.2025.1601430","url":null,"abstract":"<p><p>This comprehensive review examines the complex relationship between human immunodeficiency virus (HIV) and cardiomyopathy, focusing on the underlying molecular mechanisms, clinical manifestations, diagnostic approaches, and treatment strategies. It highlights the significant global health burden posed by HIV and its potential to cause long-term cardiovascular complications. The review investigates the pathogenesis of HIV-associated cardiomyopathy. It elucidates the intricate cellular and molecular pathways involved, including the actions of neutrophils, monocytes, macrophages, and lymphocytes in cardiac inflammation. Key signaling pathways such as TNF-NF-κB and the caspase-1 inflammasome are detailed, as they contribute to cardiac infection and injury. The clinical manifestations of HIV-associated cardiomyopathy are discussed, including fatigue, dyspnea, peripheral edema, and arrhythmias. The review outlines essential diagnostic methods, highlighting the importance of cardiac biomarkers, electrocardiography, and imaging techniques such as echocardiography and cardiac MRI. Treatment strategies are explored, encompassing lifestyle modifications, pharmacological interventions, and advanced therapies. The review underscores the importance of addressing micronutrient deficiencies, particularly selenium, in the management of HIV-associated cardiomyopathy. It also discusses the role of antiretroviral therapy and the potential benefits of intravenous immunoglobulin therapy. Furthermore, this review addresses the evolving perspective on heart transplantation for individuals with HIV. It notes that while HIV was once considered a contraindication for transplantation, recent advancements in antiretroviral therapy have led to a re-evaluation of this stance. Finally, the review identifies future research directions, emphasizing the need for biomarkers to detect at-risk patients, exploration of nutritional factors predisposing individuals to cardiomyopathy, and further investigation into advanced therapies for HIV-associated cardiomyopathy. This review significantly enhances the understanding of HIV-associated cardiomyopathy, providing valuable insights for clinicians and researchers in the fields of infectious diseases and cardiology.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1601430"},"PeriodicalIF":2.8,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12465280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk prediction models for prolonged mechanical ventilation following coronary artery bypass grafting surgery: a systematic review and meta-analysis.","authors":"Yeru Jia, Zhiyi Pei, Xiaoxin Zhang, Chen Zhang, Xiaofeng Kang","doi":"10.3389/fcvm.2025.1616003","DOIUrl":"10.3389/fcvm.2025.1616003","url":null,"abstract":"<p><strong>Objective: </strong>Prolonged mechanical ventilation (PMV) results in significant morbidity, mortality, and associated hospital costs. Models predicting PMV following Coronary artery bypass grafting (CABG) surgery were growing. However, the reliability, validity and clinical applicability of these models remain unclear. This systematic review and meta-analysis aim to provide a comprehensive quality assessment of PMV-risk prediction models for patients after CABG.</p><p><strong>Methods: </strong>Nine relevant domestic and international databases were systematically searched from inception until November 4, 2024 using PICOTS format. The Prediction Model Risk of Bias Assessment Tool (PROBAST) checklist was employed to evaluate the risk of bias and applicability of each study. A meta-analysis of the area under the curve (AUC) values from model external validations was conducted using R software.</p><p><strong>Results: </strong>Fifteen studies detailing 12 PMV-risk prediction models were included, with AUC values ranging from 0.561 to 0. 875. In the meta-analysis, the pooled AUC was 0.696 (95% CI: 0.553, 0.839, I-squared = 90.4%) for externally validated studies of three Society of Thoracic Surgeons (STS) models. The most frequently used predictors in the models were grouped into demographics, medical history, examination, and supportive therapy.</p><p><strong>Conclusions: </strong>Although studies were judged as high overall risk of bias according to PROBAST guidelines evidence from our review indicates that risk factors of PMV in Post CABG Patients include age, BMI, history of cardiac surgery, history of cardiovascular disease, COPD, EF/LVEF, IABP, and cardiopulmonary bypass.</p><p><strong>Systematic review registration: </strong>PROSPERO CRD42024608639.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1616003"},"PeriodicalIF":2.8,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12463890/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, regional, and national burden of cardiovascular diseases attributable to high body mass index from 1990 to 2021.","authors":"Liangtao Yao, Wenying Hou, Yan Zheng, Guohai Su","doi":"10.3389/fcvm.2025.1641689","DOIUrl":"10.3389/fcvm.2025.1641689","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;In recent decades, the escalating prevalence of obesity has contributed to a significant increase in the global burden of disease, with cardiovascular diseases (CVDs) emerging as the leading cause among all diseases attributable to high body-mass index (BMI). Utilizing global burden of disease (GBD) dataset from 1990 to 2021, we conducted a comprehensive analysis of the global, regional, and national trends in deaths and disability-adjusted life years (DALYs) attributable to CVDs caused by high BMI. Age-standardized mortality rate (ASMR) and age-standardized DALY rate (ASDR) were also investigated. Furthermore, we examined the associations of gender, age, and socio-demographic index (SDI) with the burden of CVDs attributable to high BMI. Finally, we assessed the evolution of health inequalities across countries and projected the global deaths and DALYs due to high BMI-related CVDs over the next two decades.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;The absolute numbers and the rates of age-standardized death, Disability-Adjusted Life Years (DALYs) per 100,000 people due to high BMI-related CVDs between 1990 and 2021 were extracted from GBD 2021. The estimated annual percentage changes (EAPCs) of high BMI-related CVDs disease burdens were calculated under the GBD's comparative risk assessment framework. Additionally, the disease burden prediction of the high BMI-related CVDs from 2022 to 2041 was performed using the bayesian age-period-cohort (BAPC) statistical model.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;In 2021, high BMI-related CVDs accounted for 1.90 million deaths globally, representing an increase of 120.63% compared to 1990, with DALYs rising by 115.47% over the same period. Notably, while ASMR and ASDR among male showed no decline, female experienced 11.30% reduction in ASMRs and 6.12% reduction in ASDR. The burden was disproportionately borne by middle-aged and older populations across all age groups. Global health inequalities related to high BMI-related CVDs demonstrated a narrowing trend from 1990 to 2010, followed by a reversal into a negative correlation and continued to widen until 2021. Looking ahead, the burden of high BMI-related CVDs is projected to rise significantly due to population growth, the increasing prevalence of obesity, and aging populations.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;The results indicate that from 1990 to 2021, the burden of CVDs caused by high BMI has significantly increased. Particular attention should be directed toward middle and low-middle SDI regions. To mitigate this burden, it is imperative to implement public health strategies that emphasize education and awareness regarding the correlation between high BMI and CVDs. Policies promoting healthy dietary habits and regular physical activity are essential for reducing the future impact of high BMI-related cardiovascular morbidity and mortality. Such measures are not only urgently needed but also offer substantial long-term benefits for g","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1641689"},"PeriodicalIF":2.8,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12465627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression levels of thymosin α1 in acute myocardial infarction patients and its correlation to cardiac function.","authors":"Liang Liu, Zhen-Fa Zhou, Xian Jin, Yu Chen, Cui-Fen Hu, Cheng-Xing Shen","doi":"10.3389/fcvm.2025.1635557","DOIUrl":"10.3389/fcvm.2025.1635557","url":null,"abstract":"<p><strong>Background: </strong>Early prediction of heart failure (HF) after acute myocardial infarction (AMI) remains a clinical challenge. There is a lack of studies investigating Thymosin α1 expression levels in AMI patients and its relationship with cardiac function post-AMI.</p><p><strong>Methods: </strong>This retrospective analysis included patients with AMI from December 2019 to February 2022. The baseline data of two groups were collected. Thymosin α1 expression level of peripheral blood plasma in AMI patients was examined by ELISA. Logistic regression analysis was applied to evaluate risk factors in-hospital cardiac dysfunction after emergency PCI in AMI patients. Receiver operating characteristic (ROC) curve was used to analyze the predictive value of the biomarker.</p><p><strong>Results: </strong>A total of 307 hospitalized patients were enrolled in this study, divided into AMI group (<i>n</i> = 274) and non-AMI group (<i>n</i> = 33). The expression level of thymosin α1 in the AMI group was significantly higher than in the non-AMI group. The AMI patients were divided into two subgroups based on the EF values. The sample size was 64 (EF < 50%) and 210 (EF ≥ 50%), respectively. The expression of thymosin α1 in the EF ≥ 50% group was significantly higher than EF < 50% group. Spearman's correlation analysis demonstrated that thymosin α1 was positively correlated with the EF value. Logistic multivariate analysis suggested that thymosin α1, NT-proBNP, and creatine kinase were independent predictors of cardiac function after AMI. The AUC of thymosin α1, NT-proBNP, and creatine kinase was 0.614, 0.714, and 0.724, respectively.</p><p><strong>Conclusion: </strong>Thymosin α1 may serve as a potential biomarker to predict cardiac function following AMI. This study may provide novel insights into the potential therapeutic targets for HF following AMI.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1635557"},"PeriodicalIF":2.8,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12463929/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retinal vascular alterations as assessment indicators of atherosclerotic cardiovascular disease risk in dyslipidemia patients.","authors":"Yu He, Guo-Hong Wang, Ming-Zhao Qin, Kai Cao, Yong-Peng Zhang, Xuan Jiao, Zheng Zhang, Qi Liu, Qian Liu, Jin-Bao Ma","doi":"10.3389/fcvm.2025.1634816","DOIUrl":"10.3389/fcvm.2025.1634816","url":null,"abstract":"<p><strong>Introduction: </strong>Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of global mortality, particularly among individuals with dyslipidemia. Traditionally, the retina has been considered a key site for examining microvascular changes. Recent evidence, however, indicates that retinal alterations may also reflect macrovascular changes. This study proposes a hypothesis in which Optical Coherence Tomography Angiography (OCTA) is utilized to evaluate retinal vascular changes as a potential biomarker for ASCVD risk assessment in dyslipidemia patients.</p><p><strong>Methods: </strong>In this cross-sectional study, 261 dyslipidemia patients were recruited and classified into non-ASCVD and ASCVD groups. OCTA was performed on all patients, with the macula and optic disc being the primary areas of assessment. The following parameters were measured: retinal vessel density (VD), retinal nerve fiber layer (RNFL) thickness, retinal thickness, foveal avascular zone (FAZ) area, FAZ perimeter, and VD within a 300 μm width ring surrounding the FAZ (FD). Ultimately, data from 231 eyes were analyzed. Comparisons of OCTA-derived metrics between groups were made, and receiver operating characteristic (ROC) curve analysis was conducted to assess the discriminatory power of these metrics for identifying ASCVD in dyslipidemia patients. The DeLong test was used to compare areas under the ROC curve for these indicators. All statistical tests were two-tailed, with significance set at <i>P</i> <i><</i> 0.05.</p><p><strong>Results: </strong>In the ASCVD group, RNFL thickness, superficial capillary plexus (SCP) parafoveal VD, SCP perifoveal VD, macular parafoveal thickness, and FD were significantly lower compared to the non-ASCVD group. ROC curve analysis confirmed the predictive value of these indicators for ASCVD identification in dyslipidemia patients. SCP parafoveal VD, SCP perifoveal VD, and FD correspond to the macular superficial capillary plexus vessel densities. When combined, these indicators formed a new composite measure, macular superficial vessel density (MSVD). The ROC curve further validated MSVD's predictive utility for ASCVD in dyslipidemia patients, with the optimal threshold identified at 143.22% using the Youden index.</p><p><strong>Conclusions: </strong>OCTA-derived indicators, particularly MSVD, demonstrate significant potential as novel biomarkers for ASCVD risk assessment in dyslipidemia patients.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1634816"},"PeriodicalIF":2.8,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12466212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Higher premature atrial contraction burden after radiofrequency ablation vs. pulsed field or cryoballoon ablation in paroxysmal atrial fibrillation: a 3-year follow-up retrospective study.","authors":"Yongxing Jiang, Chenxu Luo, Mingjun Feng, Yibo Yu, Xianfeng Du, Caijie Shen, Guohua Fu, Binhao Wang, Renyuan Fang, He Jin, Fang Gao, Huimin Chu","doi":"10.3389/fcvm.2025.1627579","DOIUrl":"10.3389/fcvm.2025.1627579","url":null,"abstract":"<p><strong>Background: </strong>Pulsed field ablation (PFA), a novel non-thermal energy source, has shown favorable 1-year data on the efficacy and safety profile in the treatment of paroxysmal atrial fibrillation (PAF). We sought to compare PFA, cryoballoon ablation (CBA), and radiofrequency ablation (RFA) in PAF treatment in a 3-year follow-up period.</p><p><strong>Methods: </strong>Patients with PAF undergoing first-time catheter ablation by PFA, CBA, and RFA were retrospectively included. The procedure endpoint was pulmonary vein isolation (PVI). Patients were followed with 24 h ambulatory ECG monitoring at 1, 3, 6, and 12 months and every 6 months thereafter. The primary efficacy endpoint was freedom from any atrial tachyarrhythmia >30 s occurring after the 3-month blanking period.</p><p><strong>Results: </strong>A total of 280 PAF patients undergoing ablation with PFA (<i>n</i> = 65), CBA (<i>n</i> = 55), or RFA (<i>n</i> = 160) were enrolled. The mean age was 60.9 ± 8.7 years, with 55.7% male patients (<i>n</i> = 156). Acute PVI was achieved in all patients. Total procedural time was shortest with PFA [91.0 (85.0, 103.0) min, <i>P</i> < 0.001], whereas fluoroscopy time was shortest with RFA [9.0 (7.0, 10.0) min, <i>P</i> < 0.001]. The peri-procedural complication rate was 2.5%. The Kaplan-Meier estimated 3-year freedom from any atrial tachyarrhythmia >30 s was 76.9% with PFA, 72.7% with CBA, and 66.9% with RFA (log-rank <i>P</i> = 0.298). The principal finding of the study was the significantly lowest premature atrial contraction (PAC) burden in non-recurrent patients treated with PFA (0.04%) compared with CBA (0.05%) and RFA (0.11%) (<i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>At the 3-year follow-up, arrhythmia freedom was similar in PFA, CBA, and RFA in patients with PAF. PFA and CBA contributed to significantly lower PAC burden compared with RFA in patients without recurrence.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1627579"},"PeriodicalIF":2.8,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12463900/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preclinical and clinical evaluation of ECM bioenvelopes for preventing CIED pocket complications.","authors":"John N Catanzaro, Thomas J Christopher, Ziad F Issa, Rajasekhar Nekkanti, Huy Phan, Afolabi Sangosanya, Hirad Yarmohammadi, Benjamin D'Souza","doi":"10.3389/fcvm.2025.1638929","DOIUrl":"10.3389/fcvm.2025.1638929","url":null,"abstract":"<p><p>Cardiac implantable electronic device (CIED) envelopes were developed to secure the device within the surgical pocket, mitigating serious risks for migration or erosion. Available CIED envelopes are either biologic, constructed from non-crosslinked extracellular matrix (ECM), or non-biologic, composed of absorbable synthetic mesh impregnated with antibiotics. Multiple studies have documented constructive remodeling following implantation of the ECM-based bioenvelopes, leading to healthy wound healing and a vascularized surgical pocket. Non-biologic materials, in contrast, trigger a foreign-body response, leading to fibrous encapsulation of the device. Indeed, clinical studies of the bioenvelope have demonstrated constructive remodeling and integration into host tissues. One observational clinical study evaluating CIED reoperations found that patients previously implanted with the bioenvelope had well-vascularized surgical pockets with site-appropriate tissues that facilitated easier device replacement, as opposed to fibrotic encapsulation of the device in patients managed with non-biologic envelopes or without envelopes. A novel, recently approved antibiotic-eluting bioenvelope is designed to provide both support for healthy wound healing plus reduced infection risk, which is a common adverse outcome of CIED implantation. This next-generation bioenvelope includes absorbable discs impregnated with the broad-spectrum antibiotics rifampin and minocycline. Preclinical studies report excellent biocompatibility, biphasic release of antibiotics over 2 weeks, and complete eradication of bacterial inoculates commonly associated with CIED infections. Therefore, this new antibiotic eluting bioenvelope adds standardized drug delivery to the device, without compromising the wound-healing benefits of non-crosslinked ECM.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1638929"},"PeriodicalIF":2.8,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12464048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sudden cardiac death in the young: single-center study of Bari autopsy cases.","authors":"Cecilia Salzillo, Marco Matteo Ciccone, Francesco Introna, Vincenzo Ezio Santobuono, Biagio Solarino, Andrea Marzullo","doi":"10.3389/fcvm.2025.1630511","DOIUrl":"10.3389/fcvm.2025.1630511","url":null,"abstract":"<p><strong>Introduction: </strong>Sudden Cardiac Death (SCD) is one of the main causes of death in the world, with a significant impact especially on young people. Sudden Cardiac Death in the Young (SCDY) is characterized by multifactorial etiology, which includes cardiomyopathies, myocarditis, channelopathies, aortopathies and coronary artery diseases. Despite progress in prevention, a significant percentage of these deaths remain unexplained without a thorough autopsy. This study aims to SCDY cases registered between 2016 and 2024, exploring the association between type of autopsy, age, sex, causes of death and temporal changes.</p><p><strong>Methods: </strong>Data relating to subjects who died for suspected SCDY, who underwent forensic, or hospital autopsy were retrospectively analysed. Investigations included type of autopsy (diagnostic or judicial), age (in years), sex, available clinical data, gross and histological findings, and cause of death. The data were divided by age groups (0-10, 11-20, 21-30, 31-40 years), sex and cause of death (arrhythmias, congenital heart defects, myocarditis, vascular dissections and cardiomyopathies). The temporal distribution of cases was also evaluated.</p><p><strong>Results: </strong>A total of 62 cases were analysed, with a prevalence of male subjects (70%). Forensic autopsies (65%) were more frequent than diagnostic findings (35%). The most represented age groups were 11-20 years (30%) and 21-30 years (25%). Unknown arrhythmias were the main cause (40%), followed by congenital heart disease (20%) and cardiomyopathy (15%). Congenital heart defects prevailed in newborns and children, while hypertrophic or arrhythmogenic cardiomyopathies were more frequently observed in young adults. Temporally, there has been a progressive increase in molecular autopsies and genetic diagnoses, in particular after the introduction of the AECVP (2017) and SCVP (2023) guidelines.</p><p><strong>Discussion: </strong>The findings highlight the need for a multidisciplinary approach to diagnosis of SCDY, with particular emphasis on molecular autopsy to identify genetic causes. The male predominance and age-related etiological differences underline the importance of specific preventive strategies, such as genetic screening in newborns and victims' relatives. The increase in diagnoses over time reflects the effectiveness of updated guidelines, but it remains crucial to expand the mandatory nature of autopsies to improve understanding of the causes of SCDY and reduce the incidence of these tragic events.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1630511"},"PeriodicalIF":2.8,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12460248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Impact of cardiac rehabilitation and treatment compliance after ST-segment elevation myocardial infarction (STEMI) in France, the STOP SCA+ study.","authors":"Emeline Laurent, Lucile Godillon, Marc-Florent Tassi, Pierre Marcollet, Stéphan Chassaing, Marie Decomis, Julien Bezin, Christophe Laure, Denis Angoulvant, Grégoire Range, Leslie Grammatico-Guillon","doi":"10.3389/fcvm.2025.1656799","DOIUrl":"https://doi.org/10.3389/fcvm.2025.1656799","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/fcvm.2025.1484401.].</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1656799"},"PeriodicalIF":2.8,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12461253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Pyroptosis in cardiovascular diseases: roles, mechanisms, and clinical implications.","authors":"Yuqing Niu, Li Wang, Yaoqing Zhang, Yanqiang Zou, Cheng Zhou","doi":"10.3389/fcvm.2025.1680298","DOIUrl":"https://doi.org/10.3389/fcvm.2025.1680298","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/fcvm.2025.1629016.].</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1680298"},"PeriodicalIF":2.8,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}